Search results for "severity"

showing 10 items of 1287 documents

Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions.

2010

Celiac disease (CD) is a gluten-triggered enteropathy, presenting with insidious clinical patterns. It can occasionally be diagnosed in asymptomatic subjects. Our aim was to define the relationship among symptoms at diagnosis, serological markers [tissue transglutaminase antibodies (tTGA), anti-endomysium antibodies (EMA) anti-actin antibodies (AAA)] and degree of mucosal damage. A total of 68 consecutive adult patients with CD were enrolled. Intestinal biopsies were scored according to the Marsh classification modified by Oberhuber: I–II minimal lesions or absent villous atrophy; IIIA partial villous atrophy; IIIB–C total villous atrophy (TVA). HLA-typing was done for all patients. No asso…

AdultGenetic MarkersMalePathologymedicine.medical_specialtyAdolescentTissue transglutaminaseEnzyme-Linked Immunosorbent AssayDiseaseSeverity of Illness IndexAsymptomaticStatistics NonparametricSerologyYoung AdultInternal MedicinemedicineHumansEnteropathyIn patientProspective StudiesIntestinal MucosaVillous atrophyAgedAged 80 and overbiologybusiness.industryMiddle Agedmedicine.diseaseImmunoglobulin AItalyEmergency Medicinebiology.proteinFemaleAntibodymedicine.symptombusinessceliac disease
researchProduct

Lung microenvironments and disease progression in fibrotic hypersensitivity pneumonitis

2022

Rationale: Fibrotic hypersensitivity pneumonitis (fHP) is an interstitial lung disease caused by sensitization to an inhaled allergen. Objectives: To identify the molecular determinants associated with progression of fibrosis. Methods: Nine fHP explant lungs and six unused donor lungs (as controls) were systematically sampled (4 samples/lung). According to microcomputed tomography measures, fHP cores were clustered into mild, moderate, and severe fibrosis groups. Gene expression profiles were assessed using weighted gene co-expression network analysis, xCell, gene ontology, and structure enrichment analysis. Gene expression of the prevailing molecular traits was also compared with idiopathi…

AdultGenetic MarkersMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyExtrinsic Allergic Alveolitisextrinsic allergic alveolitisCritical Care and Intensive Care MedicineSeverity of Illness IndexTranscriptome03 medical and health sciences0302 clinical medicineFibrosisPulmonary fibrosisMedicineHumansLungAged030304 developmental biology0303 health sciencesLungmedicine.diagnostic_testpulmonary fibrosisbusiness.industryGene Expression ProfilingInterstitial lung diseaseReproducibility of ResultsOriginal ArticlesMiddle Agedrespiratory systemmedicine.diseaseFibrosisIdiopathic Pulmonary Fibrosis3. Good healthrespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavage030228 respiratory systemCase-Control StudiesDisease ProgressionLinear ModelsFemaleHuman medicineTranscriptomebusinesstranscriptomeHypersensitivity pneumonitisAlveolitis Extrinsic AllergicAmerican journal of respiratory and critical care medicine
researchProduct

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

2018

AbstractLiver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non-invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum microRNA biomarkers with altered levels in NAFLD patients. In the present study, we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort. Moreover, miR-192, -27b, -22, -197 and -30c appeared specific for NAFLD, when compared wi…

AdultLiver CirrhosisMale0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineSeverity of Illness Indexdigestive systemArticleCohort Studies03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicinemicroRNANonalcoholic fatty liver diseasemedicineHumansCirculating MicroRNAlcsh:ScienceSerum micrornaAgedLiver injuryMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RLiquid BiopsyMiddle AgedPrognosismedicine.diseasedigestive system diseasesCirculating MicroRNA030104 developmental biologyLiverLiver biopsyCohortDisease ProgressionFemalelcsh:QbusinessBiomarkers
researchProduct

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

2018

Background & Aims The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. Methods We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fi…

AdultLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtysteatohepatitisSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineHumansMedicineIn patientProspective StudiesKeratin-18Hepatologymedicine.diagnostic_testbusiness.industryFatty liverExternal validationReproducibility of ResultsMiddle Agedmedicine.disease3. Good health030104 developmental biologyItalyLiverROC Curvenon-invasive markerLiver biopsyCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatohepatitisfibrosibusinessAlgorithmsBiomarkersLiver International
researchProduct

Impact of comorbidities on the severity of chronic hepatitis B at presentation.

2011

AIM: To evaluate the clinical relevance of each cofactor on clinical presentation of chronic hepatitis B. METHODS: Out of 1366 hepatitis B surface antigen (HBsAg) positive subjects consecutively observed in 79 Italian hospitals, 53 (4.3%) showed as the only cofactor hepatitis D virus (HDV) infection [hepatitis B virus (HBV)/HDV group], 130 (9.5%) hepatitis C virus (HCV) (group HBV/HCV), 6 (0.4%) human immunodeficiency virus (HIV) (group HBV/HIV), 138 (10.2%) alcohol abuse (group HBV/alcohol); 109 (8.0%) subjects had at least two cofactors and 924 were in the cofactor-free (CF) group. RESULTS: Compared with patients in group CF those in group HBV/alcohol were older and more frequently had ci…

AdultLiver CirrhosisMaleHBsAgmedicine.medical_specialtyCirrhosisBrief ArticleHepatitis C virusAlcohol abuseLiver CirrhosiHIV InfectionsComorbiditymedicine.disease_causeGastroenterologyChronic hepatitis BSeverity of Illness IndexLiver diseaseHepatitis B ChronicHepatitis B virus/hepatitis C virus dual infectionInternal medicinemedicineHBVHumansAge FactorHIV InfectionAgedHepatitis B virusbusiness.industryGastroenterologyAge Factorsvirus diseasesGeneral MedicineHepatitis CMiddle Agedmedicine.diseaseHepatitis DHepatitis Cdigestive system diseasesHepatitis DAlcoholismItalyImmunologyFemaleHepatitis D virusbusinessHepatitis B virus/hepatitis D virus dual infectionHuman
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation

2013

BACKGROUND & AIMS: Histological assessment of fibrosis progression is currently performed by staging systems which are not continuous quantitative measurements. We aimed at assessing a quantitative measurement of fibrosis collagen proportionate area (CPA), to evaluate fibrosis progression and compare it to Ishak stage progression. METHODS: We studied a consecutive cohort of 155 patients with recurrent HCV hepatitis after liver transplantation (LT), who had liver biopsies at one year and were subsequently evaluated for progression of fibrosis using CPA and Ishak staging, and correlated with clinical decompensation. The upper quartile of distribution of fibrosis rates (difference in CPA or Is…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyLiver transplantationGastroenterologySeverity of Illness IndexCohort StudiesYoung AdultFibrosisRecurrenceRisk FactorsInternal medicineSeverity of illnessBiopsyAzathioprinemedicineImage Processing Computer-AssistedHumansDecompensationAgedHepatitisHepatologymedicine.diagnostic_testliver transplantationbusiness.industryHepatitis CMiddle Agedmedicine.diseaseHepatitis CSurgeryLiverWithholding TreatmentDisease ProgressionRegression AnalysisFemaleCollagenbusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.

2014

Background & Aims: In Chronic Hepatitis C (CHC), the influence of steatosis on liver stiffness measurement (LSM) is still debated. We assessed the impact of steatosis and its ultrasonographical sign – bright liver echo pattern (BLEP) – on LSM values and on transient elastography (TE) accuracy for the diagnosis of liver fibrosis, in a cohort of consecutive patients with Genotype 1 (G1) CHC. Methods: Patients (n = 618) were assessed by clinical, ultrasonographic and histological (Scheuer score) features. TE was performed using the M probe. Results: Male gender (p = 0.04), steatosis as continuous variable (p <0.001), severity of necroinflammation (p = 0.02) and stage of fibrosis (p <0.001) wer…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisGenotypeBiopsyComorbidityHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologySensitivity and SpecificitySeverity of Illness IndexCohort StudiesFibrosisInternal medicineUltrasoundmedicineHumansNon-invasiveEvaluationAgedRetrospective StudiesUltrasonographySettore MED/12 - GastroenterologiaCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseElasticityFatty LiverLiverLiver biopsyCohortFibroscan®Cirrhosis; Evaluation; Fibroscan®; Non-invasive; UltrasoundFemaleSteatosisbusinessTransient elastographyJournal of hepatology
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in pat…

2014

Background & Aims The accuracy of noninvasive tools for the diagnosis of severe fibrosis in patients with nonalcoholic fatty liver disease(NAFLD) in clinical practice is still limited. We aimed at assessing the diagnostic performance of combined noninvasive tools in two independent cohorts of Italian NAFLD patients. Methods We analysed data from 321 Italian patients(179 Sicilian-training cohort, and 142 northern Italy-validation cohort) with an histological diagnosis of NAFLD. Severe fibrosis was defined as fibrosis ≥ F3 according to Kleiner classification. The APRI, AST/ALT, BARD, FIB-4, and NFS scores were calculated according to published algorithms. Liver stiffness measurement(LSM) was …

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyAdolescentLSM ; NAFLD ; NFSBiopsySettore MED/08 - Anatomia PatologicaGastroenterologySeverity of Illness IndexLSM; NAFLD; NFS; Adolescent; Adult; Aged; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Biopsy; Female; Humans; Italy; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Young Adult; Severity of Illness Index; Hepatology; Medicine (all)Young AdultFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDNonalcoholic fatty liver diseaseSeverity of illnessBiopsyNFSmedicineHumansLSMAspartate AminotransferasesAgedRetrospective StudiesSettore MED/12 - Gastroenterologiabiologymedicine.diagnostic_testHepatologybusiness.industryMedicine (all)Retrospective cohort studyAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseAlanine transaminaseItalyLiverArea Under CurveCohortbiology.proteinFemalebusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct